arrow_back Back Filing freshness 10-K Q4 FY2026 SEC EDGAR

Propanc Biopharma, Inc.

PPCB
$1.65 ▼ -0.09 (-4.90%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
65 Visible periods
23 Metrics
Peer-ranked Benchmarks
Price Chart
7
Health
Poor
Bearish
auto_awesome

Analytical Summary

Propanc Biopharma, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap —
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC -29.0% ↗
FCF / Share None
Trailing P/E —
Price / Book 0.6x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

65-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-4.57M
↓ -12.3% —
FCF / Share Free cash flow per share
$-0.05
↑ +32.0% —
Long-Term Debt Long-term obligations
$55.00K
— 0.0% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
2
Financial Health ↓
2
Cash Quality ↓
31

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 19 years · 65 quarters